SLNCF — Silence Therapeutics Balance Sheet
0.000.00%
- $291.43m
- $280.16m
- $0.56m
Annual balance sheet for Silence Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | 10-K | 10-K | 10-K |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 99.5 | 86.1 | 68.8 | 121 | 11.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 11.5 | 21 | 24 | 52.9 | 98.5 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 117 | 117 | 103 | 187 | 119 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.63 | 2.66 | 2.31 | 1.98 | 1.75 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 130 | 130 | 119 | 203 | 131 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 20.5 | 26.2 | 22.3 | 16.8 | 13.6 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 119 | 103 | 97.5 | 68.6 | 69.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 11.5 | 26.7 | 22 | 134 | 62.3 |
| Total Liabilities & Shareholders' Equity | 130 | 130 | 119 | 203 | 131 |
| Total Common Shares Outstanding |